Low molecular weight heparin (LMWH) or enoxaparin that inhibits activated factor X is now widely recommended as an early anticoagulation therapy unless there is contraindication.3, 5Its anti-inflammatory properties further make LMWH, a preferred choice in mitigating cytokine storms in COVID-19 patients.3, 5Cytokine burst leading to sepsis is one of the primary reasons for the ARDS drive that could be worsened with the accumulation of coagulation factors in the lungs.6However, the obscurity of ARDS remains a hurdle in making decisive treatment choices for patients. The gene discussed is F10; the disease is acute respiratory distress syndrome.